DiscoveryProbe™ FDA-approved Drug Library: Enabling Precision Drug Repurposing and Rare Disease Therapeutics

Introduction

The rapid evolution of biomedical research has intensified the demand for advanced compound libraries that enable efficient discovery of novel therapeutic applications for existing drugs. The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) distinguishes itself as a comprehensive, regulatory-vetted collection of 2,320 bioactive compounds, meticulously curated for high-throughput and high-content screening. This article delves deeper than prior overviews—such as those focused on workflows or cancer immunomodulation—by examining the library's transformative role in rare disease research, especially in the context of drug repositioning for orphan and ultra-orphan disorders. We further illuminate its unique scientific utility through the lens of recent breakthrough work on mucopolysaccharidosis-plus syndrome (MPSPS), offering a perspective on how this resource accelerates discovery where traditional methods fall short.

The Scientific Foundation of the DiscoveryProbe™ FDA-approved Drug Library

Composition and Mechanistic Breadth

The DiscoveryProbe FDA-approved Drug Library encompasses clinically approved compounds from major global agencies (FDA, EMA, HMA, CFDA, PMDA) and recognized pharmacopeias. Its breadth covers receptor agonists and antagonists, enzyme inhibitors, ion channel modulators, and signal pathway regulators—strategically selected for their well-characterized pharmacological actions. Exemplary compounds such as doxorubicin, metformin, and atorvastatin anchor the collection in clinical relevance.

Each compound is supplied as a pre-dissolved 10 mM DMSO solution, ensuring reproducibility and compatibility with automated liquid handling. Researchers can select from 96-well microplates, deep well plates, or 2D barcoded screw-top tubes, with stability validated for up to 24 months at -80°C. This design facilitates seamless integration with both high-throughput screening (HTS) and high-content screening (HCS) platforms, providing a robust foundation for pharmacological target identification, drug repositioning screening, and mechanistic pathway exploration.

Precision and Quality in Screening

Unlike traditional chemical libraries, the DiscoveryProbe library eliminates ambiguity by ensuring all compounds possess established safety, toxicity, and pharmacokinetic profiles. This enables translational research pipelines to advance from screening hits to in vivo validation and clinical investigation with unprecedented speed and confidence—especially vital for rare or neglected diseases where new drug development is often economically unviable.

Comparative Analysis: Addressing the Gaps Left by Conventional Approaches

While prior overviews have highlighted the DiscoveryProbe™ library’s high-throughput capabilities and impact on mainstream applications (see summary), this article focuses on its unique value for uncharted research territories—namely, precision drug repositioning for rare genetic and metabolic disorders.

Existing articles, such as the enzyme inhibitor screening overview, provide in-depth mechanistic insights, especially regarding CYP3A4 modulation and personalized medicine. Our analysis goes further by positioning the library as a resource for hypothesis-free phenotypic screening, enabling the discovery of entirely unexpected mechanisms—as exemplified in the recent identification of triclabendazole for MPSPS. Similarly, while the immune checkpoint modulation piece explores translational oncology, we present a new paradigm: leveraging regulatory-approved molecules for ultra-rare, mechanistically elusive diseases.

Case Study: Unveiling Triclabendazole’s Potential for Mucopolysaccharidosis-Plus Syndrome

Background and Disease Context

Mucopolysaccharidosis-plus syndrome (MPSPS, OMIM #617303) is a devastating, ultra-rare genetic disorder characterized by pathological accumulation of glycosaminoglycans (GAGs). Patients experience severe systemic manifestations including renal and hematopoietic failure, bone deformities, and drastically reduced life expectancy, with no disease-modifying therapies currently available.

Pioneering Drug Repositioning via FDA-Approved Bioactive Compound Library

In a landmark study (Terawaki et al., 2025), researchers harnessed an FDA-approved bioactive compound library to identify novel interventions for MPSPS. Through unbiased phenotypic screening, triclabendazole—a drug traditionally used to treat parasitic infections—emerged as a potent suppressor of GAG accumulation in cellular and murine MPSPS models. Notably, this discovery was unattainable by conventional target-driven strategies, owing to the incomplete understanding of the disease’s molecular etiology.

The DEFAC (Differential Expression of Functional Autophagy Components) method enabled single-cell resolution assessment of protein function and autophagy, revealing that the disease-associated VPS33A mutation preserved autophagic capacity. This insight redirected therapeutic efforts toward small molecules capable of modulating substrate accumulation, rather than attempting to restore lysosomal enzyme activity directly.

The DiscoveryProbe FDA-approved Drug Library, with its breadth of mechanism-diverse compounds and high-content screening compatibility, is ideally suited for such phenotypic screening approaches. By enabling direct evaluation of over 2,300 regulatory-vetted molecules, it empowers the rapid identification of unexpected therapeutic candidates—demonstrated most recently by the repurposing of triclabendazole for MPSPS (Terawaki et al., 2025).

Advanced Applications in Rare Disease and Precision Medicine

Expanding Beyond Traditional Disease Models

While the DiscoveryProbe library’s utility in cancer and neurodegenerative disease research is well documented (see detailed mechanistic review), its greatest untapped potential lies in accelerating drug discovery for rare, complex, or poorly characterized disorders. These include lysosomal storage diseases, metabolic syndromes, and orphan genetic mutations—areas where traditional target-based drug discovery is often stymied by incomplete molecular understanding and limited commercial incentive.

Phenotypic Screening and High-Content Analysis

By integrating high-content screening compound collection tools with disease-relevant cellular and animal models, researchers can systematically interrogate the therapeutic potential of every molecule in the library. This approach is particularly powerful for disorders where the molecular target may be unknown, multifactorial, or context-dependent. The DiscoveryProbe FDA-approved Drug Library’s pre-dissolved, automation-compatible format enables rapid, reproducible screening across diverse assay systems, from CRISPR-engineered patient-derived cells to organoids and in vivo models.

Accelerating Drug Repositioning and Translational Impact

Drug repositioning screening using a library of this caliber offers unmatched translational velocity. Hits identified from the DiscoveryProbe™ FDA-approved Drug Library can rapidly progress to preclinical validation, leveraging the compounds’ established safety and pharmacokinetic profiles. This drastically reduces the time and cost required to bring new therapies to patients suffering from neglected or ultra-rare conditions—a key differentiator from libraries focused solely on novel chemical matter.

Technical Advantages for Advanced Screening Programs

Stability, Flexibility, and Data Integrity

The DiscoveryProbe library is engineered for scientific rigor. Solution stability is guaranteed for 12 months at -20°C and up to 24 months at -80°C, maintaining compound integrity throughout extended screening campaigns. Multiple format options—96-well plates for high-throughput platforms, deep well plates for high-content workflows, and individual screw-top tubes for custom assay development—support a wide range of experimental designs.

Facilitating Large-Scale and Custom Assays

Researchers pursuing pharmacological target identification or enzyme inhibitor screening in complex disease models benefit from the library’s flexibility and automation compatibility. This allows seamless scaling from small pilot screens to genome-wide, multi-parameter phenotypic assays—enabling projects that would be impractical or cost-prohibitive with less rigorously curated libraries.

Robust Support and Interoperability

APExBIO’s reputation for quality and technical support ensures that the DiscoveryProbe FDA-approved Drug Library is not only scientifically robust but also accessible to a broad spectrum of research organizations, from academic laboratories to industry consortia. The resource is further enhanced by comprehensive documentation, batch records, and data support—critical for regulatory submissions and collaborative translational efforts.

Conclusion and Future Outlook

The DiscoveryProbe™ FDA-approved Drug Library represents a paradigm shift in drug discovery and repositioning, particularly for rare and mechanistically complex diseases where innovation is most urgent. By enabling unbiased, high-throughput, and high-content phenotypic screening of clinically vetted molecules, it bridges the gap between basic research and translational impact—demonstrated powerfully in the recent identification of triclabendazole as a therapeutic for MPSPS (Terawaki et al., 2025).

This article extends the conversation beyond earlier content on workflows, enzyme modulation, or immune checkpoint applications by emphasizing the library’s unique role in rare disease therapeutics and hypothesis-free discovery. As the field advances, the integration of such resources with cutting-edge model systems and data analytics promises to further accelerate the development of effective therapies for both common and neglected diseases. For researchers seeking to drive innovation in signaling pathway regulation, enzyme inhibitor screening, and beyond, the DiscoveryProbe™ FDA-approved Drug Library from APExBIO remains an indispensable asset at the forefront of biomedical science.